. 2021 Apr 22;18(2):14791641211011016. doi: 10.1177/14791641211011016
© The Author(s) 2021
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Figure 1.
Meta-analysis of SGLT2 inhibitors and eight safety endpoints.